Nuclear Ca 2+ plays a pivotal role in the regulation of gene expression. IP 3 (inositol-1,4,5-trisphosphate) is an important regulator of nuclear Ca 2+ . We hypothesized that the CaR (calcium sensing receptor) stimulates nuclear Ca 2+ release through IICR (IP 3 -induced calcium release) from perinuclear stores. Spontaneous Ca 2+ oscillations and the spark frequency of nuclear Ca 2+ were measured simultaneously in NRVMs (neonatal rat ventricular myocytes) using confocal imaging. CaR-induced nuclear Ca 2+ release through IICR was abolished by inhibition of CaR and IP 3 Rs (IP 3 receptors). However, no effect on the inhibition of RyRs (ryanodine receptors) was detected. The results suggest that CaR specifically modulates nuclear Ca 2+ signalling through the IP 3 R pathway. Interestingly, nuclear Ca 2+ was released from perinuclear stores by CaR activator-induced cardiomyocyte hypertrophy through the Ca 2+ -dependent phosphatase CaN (calcineurin)/ NFAT (nuclear factor of activated T-cells) pathway. We have also demonstrated that the activation of the CaR increased the NRVM protein content, enlarged cell size and stimulated CaN expression and NFAT nuclear translocation in NRVMs. Thus, CaR enhances the nuclear Ca 2+ transient in NRVMs by increasing fractional Ca 2+ release from perinuclear stores, which is involved in cardiac hypertrophy through the CaN/NFAT pathway.
Introduction
Ca 2+ plays an important role in regulating nuclear function, including gene transcription, DNA replication, cell growth, differentiation, survival and death. Due to the characterization of the nucleoplasmic reticulum, evidence favouring an independent intranuclear Ca 2+ signalling system has emerged. The nucleoplasmic reticulum is a nuclear Ca 2+ store organelle, contiguous with the ER (endoplasmic reticulum)/SR (sarcoplasmic reticulum) network and the nuclear envelope (Echevarría et al., 2003; Marius et al., 2006) . Studies have demonstrated that the nucleus contains the complete machinery for both IP 3 R (inositol-1,4,5-trisphosphate receptor)-and RyR (ryanodine receptor)-dependent Ca 2+ release (Marius et al., 2006; Guatimosim et al., 2008) . Recently, several studies have suggested that protrusions of the nuclear envelope, which contains IP 3 Rs, extend into the nuclear interior, resulting in faster and more sensitive Ca 2+ responses to IP 3 Rs stimulation in the region of the nucleoplasm compared with the cytoplasm (Echevarría et al., 2003; Luo et al., 2008) . These observations imply that the roles of IP 3 R-mediated Ca 2+ signalling in cardiac development or remodelling in response to stress are consistent with the recent finding that IP 3 R-mediated nuclear Ca 2+ release is involved in the activation of nuclear signal transduction for cell growth (Giorgi et al., 2010) .
The CaR (calcium sensing receptor) is a G q -protein-coupled receptor that stimulates PLC (phospholipase C) activity and increases intracellular IP 3 levels, leading to [Ca 2+ ] i (intracellular Ca 2+ ) release. Stimulation of IICR (IP 3 -induced calcium release) downstream of plasma membrane receptors promotes hypertrophy, and IICR is a regulator of hypertrophic gene transcription (Mackenzie et al., 2002; Zima and Blatter, 2004) . IICR can also activate the CaMK (calmodulin-dependent protein kinase) and induce expression of a synthetic MEF2 (cardiomyocyte enhancer factor 2) reporter in cardiac myocytes (Wu et al., 2006) . The data suggest that IICR is a regulator of cardiomyocyte hypertrophy.
We therefore have tested whether autonomous localized nuclear Ca 2+ signalling exists and how it is regulated by the CaR. Evidence is also provided that the CaR regulates cardiomyocyte function by the nuclear Ca 2+ transient.
Materials and methods

Isolation and culture of NRVMs (neonatal rat ventricular myocytes)
After isolation, cells were plated on to laminin-coated 35-mm dishes at 0.5610 3 cells/mm 2 and cultured for 48 h in 4:1 DMEM (Dulbecco's modified Eagle's medium) containing 10% fetal bovine serum, 4 mM L-glutamine, 100 units/ml penicillin/streptomycin and 0.1 mM 5-bromo-2-deoxyuridine to inhibit fibroblast proliferation. The medium was changed to serum-free 6 h before use to eliminate any stimulation of cell growth by the serum. The cells were harvested after 48-55 h of culture.
Experimental protocol
Three days after seeding, the NRVMs were starved in serum-free DMEM for 12 h. The NRVMs were divided randomly into 5 groups: (i) control: the NRVMs were cultured with DMEM for 72 h; (ii) AngII (angiotensin II): the NRVMs were treated with 100 nM AngII for 48 h; (iii) GdCl 3 : the NRVMs were incubated with 30 mM GdCl 3 (a specific agonist of CaR) for 48 h; (iv) GdCl 3 +NPS-2390: the NRVMs were treated with 10 mM NPS-2390 (a specific inhibitor of the CaR) and 30 mM GdCl 3 ; and (v) GdCl 3 +CsA (cyclosporin A): this treatment was similar to that of group 3, except that the NRVMs were pre-incubated with 100 mg/ml CsA [a specific inhibitor of the Ca
2+
-dependent phosphatase CaN (calcineurin)] for 1 h.
Measurement of NRVMs diameter
After digestion, the NRVMs were centrifuged and resuspended in DMEM, and the number of NRVMs was counted in at least 3 dishes per group using phase-contrast microscopy. Cell diameter was measured using the Image J analysis system. Ten fields were randomly chosen for each group, and 10 NRVMs were determined for every field.
Immunofluorescence
After treatment, the NRVMs were washed with PBS, fixed with 4% (v/v) PFA (paraformaldehyde) in PBS for 10 min, and permeabilized with 0.3% Triton X-100 for 10 min. After blocking in 1% BSA and 0.1% Tween 20 for 30 min, the NRVMs were stained with FITC-conjugated phalloidin for 2 h, washed in PBS and 0.1% Tween 20. As indicated, some cells were stained with DAPI (49,6-diamidino-2-phenylindole; 25 mg/ml, Roche) for 1 h, and mounted for fluorescence microscopy (Leica Corporation) as described previously (Morel et al., 2003 ) was measured in intact and permeabilized NRVMs with fluorescence laser scanning confocal microscopy. Intact NRVMs were loaded with 4 mM fluo-4/AM (fluo-4 acetoxymethyl ester; Molecular Probes) at 37uC for 30 min and washed for 20 min with a Hepes-buffered salt solution (135 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 10 mM Hepes and 11 mM glucose 11, at pH 7.4). Confocal images of fluorescence (l ex at 488 nm and l em at .515 nm) were obtained using a Zeiss LSM 510 inverted microscope equipped with a 663 oil immersion objective (NA 1.4). [Ca 2+ ] i increase is presented as background-subtracted normalized fluorescence (F/F 0 ), where F is the fluorescence intensity and F 0 is the baseline fluorescence determined by averaging 50 images with no activity. Ca 2+ sparks were analysed using customer-devised routines coded in the IDL (Interactive Data Language; Research System). All experiments were performed at room temperature (22-24uC).
Western blot analysis
Total protein and nuclear protein extracts from the NRVMs were as previously described (Mather, 1988; Quignard et al., 2001) . Samples containing 40 mg of protein from the different experimental groups were separated by SDS/10% PAGE and transferred to nitrocellulose membranes by electroblotting (300 mA for 2 h). The membranes were blocked in TBS-T [137 mM NaCl, 20 mM Tris (pH 7.6), and 0.1% (v/v) Tween 20] containing 5% (w/ v) non-fat dried skimmed milk powder at 37uC for 1 h. The membranes were incubated overnight at 4uC with antibodies against the CaR (1:2500) and CaN (1:800) and NFAT (nuclear factor of activated T-cells) (1:200). The membranes were incubated with a secondary antibody (AP-IgG; Promega) diluted 1:5000 in TBS-T for 1 h at room temperature. The volumes of the protein bands were quantified by a Bio-Rad Chemi DocTM EQ densitometer and Bio-Rad Quantity One software (Bio-Rad Laboratories). b-Actin was used as an internal control.
Statistical analysis
The results are presented as means¡S.E.M. Comparisons were performed using one-way ANOVA. The data were considered significantly different for P,0.05. 
Expression and localization of IP 3 R in NRVMs
To determine the role of the IP 3 R in Ca 2+ signalling in NRVMs, we examined IP 3 R expression and localization. The expression of the type 2 and 3 IP 3 Rs was confirmed ( Figure 1A) ; immunofluorescence showed a transnuclear distribution of the type 2 IP 3 R, and a cytoplasmic and perinuclear distribution of the type 3 IP 3 R. The perinuclear presence of the type 2 RyR was also identified ( Figure 1B Figure 2B ). Nevertheless, the amplitude of sparks in the NPS-2390 or 2-APB group was significantly lower than in the GdCl 3 group ( Figure 2C ).
CaR-mediated cardiomyocyte hypertrophy
Treatment with GdCl 3 and AngII for 48 h in cultures of spontaneously beating NRVMs induced a characteristic hypertrophic effect, which was confirmed by a number of well-characterized hallmarks. Morphological analysis showed an enlarged cell size in the AngII and GdCl 3 groups but not in the NPS-2390-or 2-APBtreated NRVMs ( Figure 3A) . The number of cells in the AngII-and GdCl 3 -treated groups was less than that of the control group. The number of cells in the NPS-2390-or 2-APB-treated hypertrophied groups was higher than that of the AngII-and GdCl 3 -treated groups ( Figure 3B ). Additionally, both the NPS-2390 and 2-APB treatment significantly reduced the total protein content compared with the AngII-and GdCl 3 -treated NRVMs ( Figure 3C ). Together, the data suggest that the CaR may be involved in cardiomyocyte hypertrophy.
To further confirm the effect of GdCl 3 on cardiomyocyte hypertrophy, changes in ANP, a marker of cardiomyocyte hypertrophy, were determined by Western blotting. We found that the expression of ANP in the AngII and GdCl 3 groups was significantly increased compared with the NPS-2390 and 2-APB groups ( Figure 3D ).
CaR alters the CaN/NFAT pathway through nuclear Ca 2+ regulation
The CaN is of central interest as a key transducer in the Ca 2+ -activated signalling pathway, particularly in the field of cardiac hypertrophy. To determine whether CaN is involved in the hypertrophic effects of the different treatments described above, NRVMs were treated with GdCl 3 . Expression of CaN was significantly increased in the GdCl 3 group compared with the NPS-2390 and 2-APB groups ( Figure 4A) .
A major pathway regulated by CaN involves the NFAT, which, upon dephosphorylation, translocates to the nucleus and leads to the transcription of several genes. To address the involvement of CaN/NFAT, NRVMs were pretreated with CsA, a classical inhibitor of CaN, before analysing the localization of NFAT in the cell. A higher number of GdCl 3 -treated cells with nuclear NFAT were seen compared with the GdCl 3 +CsA group. AngII treatment was used as a positive control for NFAT translocation to the nucleus. As expected, AngII treatment led to higher percentage of control cells with nuclear NFAT (Figure 4B ). To confirm the effect of GdCl 3 on translocation of NFAT, nuclear NFAT were determined by Western blotting. Expression of nuclear NFAT in the NPS-2390 and CsA groups was significantly decreased compared with the AngII and GdCl 3 groups ( Figure 4C ). 
Discussion
We have demonstrated that the CaR stimulates IP 3 -induced nuclear Ca 2+ release, which regulates cardiac myocyte hypertrophy through the activation of the CaN/NFAT pathway. Expression of the CaR has been observed in various cell types, including NRVMs (Sun et al., 2006 (Patterson et al., 2002; Tu et al., 2007) . Several studies have shown that the nucleus of cardiomyocytes contains a nucleoplasmic reticulum, invaginations of the ER and the nuclear envelope penetrating into the nuclear interior. The IP 3 R is expressed along the intranuclear structure of the nucleoplasm (Brown and MacLeod, 2001; Tu et al., 2007) . Our immunofluorescence experiments show transnuclear localization of the type 2 IP 3 R, and cytoplasmic and perinuclear localization of the type 3 IP 3 R. We also demonstrated the perinuclear localization of the type 2 RyR. Luo et al. (2008) have also demonstrated the perinuclear localization of the type 2 IP 3 R and type 2 RyR in rat cardiomyocytes. Functional type 2 and 3 IP 3 Rs and RyRs exist on the nuclear envelope of cardiac myocytes (Luo et al., 2008) . While involved in [Ca 2+ ] i release by IP 3 , the IP 3 Rs are also abundantly expressed in the embryonic heart. Furthermore, the IP 3 Rs and IP 3 -synthesizing machinery exists in the inner nuclear membrane, resulting in a functional Ca 2+ release in the nucleus in response to extranuclear and/or extracellular stimuli (Echevarría et al., 2003; Bare et al., 2005; Wu et al., 2006 transients and increases in CaN expression, which induces the translocation of NFAT to the nucleus, resulting in gene transcription (Wilkins et al., 2004; Higazi et al., 2009 ). The expression of CaN and NFAT nuclear translocation is inhibited by CsA ( Figure 4B ). The result of Western blotting of nuclear NFAT supports the conclusion ( Figure 4C ). We further show that the nuclear Ca 2+ release resulting from the stimulation of the CaR regulates the CaN/NFAT signalling pathway in the NRVMs. This supports the following conclusions: (i) CaN activated by the CaR is involved in IICR-induced ANP expression ( Figures 3D and 4A) ; (ii) GdCl 3 stimulation with NPS-2390-or 2-APB-altered CaN expression indicates a role of CaR-stimulated IICR in the nucleus for the activation of the CaN/NFAT pathway ( Figure 4A) ; and (iii) activation with AngII and GdCl 3 is sufficient for nuclear NFAT translocation and accumulation ( Figures 4B and 4C ). Cardiac hypertrophy occurs as an adaptive response to various cardiovascular conditions such as hypertension, ischaemic heart disease or mutations in sarcomeric genes. The CaN/ NFAT pathway mediates the gene transcription required for pathological hypertrophy (Aronow et al., 2001; Nakayama et al., 2010) . We have shown that nuclear CaN and Ca 2+ are required for ANP expression and that increased nuclear Ca 2+ increases nuclear NFAT translocation ( Figures 4B and 4C) . Moreover, morphological analysis showed various changes in the size, total protein content and cell number of hypertrophied NRVMs by various stimuli. Compared with the control NRVMs or the NPS-2390-and 2-APB-treated cells, the total protein content was increased, and an increase in the size of the hypertrophied NRVMs was induced by AngII and GdCl 3 , along with a concomitant decrease in cell number. We show not only that CaN is activated by the CaR stimulation of nuclear Ca 2+ release from the perinuclear stores and is involved in IICR-induced ANP expression but also that the CaN/NFAT pathway is a key mechanism by which the requisite IP 3 -stimulated increase in nuclear Ca 2+ release is coupled to the transcriptional machinery for the induction of hypertrophy. We conclude that CaR-induced hypertrophy of NRVMs is involved in CaN/NFAT pathway activation in response to nuclear Ca 2+ release mediated by the IP 3 R. In summary, nuclear Ca 2+ signalling contributes to the regulation of cardiomyocyte function. We report the novel finding that the involvement of the CaR in IP 3 -stimulated increases in nuclear Ca 2+ and its engagement of the CaN/NFAT pathway, an essential signal for the induction of hypertrophy. The specific effects of nuclear Ca 2+ release via other pathways involved in hypertrophy require further investigation. Inhibition of the CaR may be a clinically relevant target due to its potential effect of reducing pathological hypertrophic growth propensity.
